Skip to content

Evaluation of quantitative analysis of liver fibrosis by IVIM-DWI and Fibroscan in chronic liver disease.

Evaluation of quantitative analysis of liver fibrosis by IVIM-DWI and Fibroscan in chronic liver disease. - Evaluation of quantitative analysis of liver fibrosis by IVIM-DWI and Fibroscan in chronic liver disease.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000040636
Enrollment
100
Registered
2020-06-10
Start date
2019-07-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic liverdisease

Interventions

Acquisition of MRI images

Sponsors

Juntendo University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Chronic liver impairment is suspected, and MRI of liver, blood test, and Fibroscan were performed. Pathological examination is not mandatory. 2.Hematological tests (hemoglobin, white blood cell count, white blood cell fraction, platelet count), and blood biochemical tests (ALP, total bilirubin, albumin, AST, ALT, total protein, LDH, HbA1C, ChE, total cholesterol, type) 4 collagen and M2GPI are included). 3.Patients who obtained written informed consent from the patient during the echo examination and MRI examination (includ IVIM-DWI examination)

Exclusion criteria

Exclusion criteria: 1.Those who noticeably deteriorated image quality due to physical movement during the process. 2.Those who discontinue the test due to claustrophobia. 3.Those who refuse to participate due to disclosure of research information. 4.Those who the research director judges to be inappropriate as a research target.

Design outcomes

Primary

MeasureTime frame
To confirm the advantages of IVIM-DWI quantitative evaluation compared with Fibroscan

Countries

Japan

Contacts

Public ContactKoji Murakami

Juntendo University Hospital Radiology

k-murakami@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026